Conclusions
PsA, axial disease
In summary, irrespective of the predefined assessment for axial involvement applied (investigator judgement alone or both investigator judgement and PRO-based criteria), patients with active PsA and axial involvement demonstrated improvements in their axial symptoms with upadacitinib 15 mg, often with greater numerical responses versus adalimumab, which were maintained over long-term follow-up (56 weeks) in two phase 3 studies. Safety results for upadacitinib 15 mg were generally comparable between patients with or without axial involvement. These data provide important information for treating clinicians on the efficacy and safety of upadacitinib 15 mg in axial disease and may help guide treatment decisions for PsA patients with axial involvement.